Richter and Fuji further strengthen their strategic cooperation

According to the information, investments and innovations in women’s healthcare remain insufficient. Globally, research and development in this area accounts for less than 5 percent of total pharmaceutical R&D, which limits future treatment options, but at the same time offers significant opportunities for innovative companies willing to invest in this area.

– they announced.

During the collaboration, the two companies will jointly acquire or license promising external drug candidates. Together with internal projects, these initiatives aim to accelerate innovation and provide advanced therapeutic solutions in the field of gynecology worldwide.

To promote innovation in gynecology, Richter recently established a research center for original gynecological research and development in Belgium and strengthened its research and development activities in Budapest. This center will play a key role in promoting joint development efforts between Richter and Fuji.

The information recalled that the two companies have been in a close partnership in the field of gynecology for many years. The collaboration resulted in Fuji’s development, commercialization and marketing of Alyssa®, a drospirenone and estetrol-containing product for the treatment of painful menstruation, in Japan, and the marketing of Nextstellis™, an oral contraceptive, in Thailand.

Fuji also holds the marketing rights for Richter’s estetrol-based hormone replacement therapy product candidate in Japan and the ASEAN (Association of Southeast Asian Nations) regions. The product candidate recently received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) under the brand name FYLREVY®.